Lecanemab Reduces Blood Biomarkers of Alzheimer Disease - Practical Neurology
Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer's Disease: Lecanemab (BAN2401) - touchNEUROLOGY
Advisory Council January 2018 Meeting Presentation: Overview on NIA Preclinical Pipeline | ASPE
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research & Therapy | Full Text
Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401's Mechanism of Action
Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions - IOS Press
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise - Biological Psychiatry
Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment | Expert Reviews in Molecular Medicine | Cambridge Core
Biogen and Eisai try to defend Alzheimer's drug BAN2401 against skeptics | Fierce Biotech
S-1/A
Chad Swanson, PhD, on the Promising Effect of BAN2401 on Alzheimer Disease Progression
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease | Nature Reviews Neurology
Novel Treatments for Alzheimer Disease Disorders - Practical Neurology
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
The Development of Pharmacological Therapies for Alzheimer's Disease | SpringerLink
Biogen Results: Time To Change The Paradigm In Alzheimer's Disease (NASDAQ:BIIB) | Seeking Alpha
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research & Therapy | Full Text
LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Alzheon Pipeline | Preserving Future Memories
Alzheimer's disease: Recent treatment strategies - ScienceDirect
Current clinical trials for the treatment of Alzheimer's disease (as of... | Download Table
EISAI ANNOUNCES THE START OF THE FIRST CLINICAL STUDY OF BAN2401, A NOVEL MONOCLONAL ANTIBODY TARGETING THE NEUROTOXIC PROTOFIBRILS BELIEVED TO CAUSE ALZHEIMER'S DISEASE | News Release：2010 | Eisai Co., Ltd.
Alzheimer's disease drug development pipeline: 2017 - Cummings - 2017 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
BioArctic's new collaboration with Eisai on BAN2401
View of Immunotherapy Targeting Amyloid-β Peptides in Alzheimer's Disease | Exon Publications
